Sept 24 (Reuters) - Pharmacy middlemen are working on a

proposal to change some of their business practices to avoid new

regulation from the Trump administration, Bloomberg News

reported on Wednesday, citing people familiar with the

discussions.

The Pharmaceutical Care Management Association, a key

lobbying group for pharmacy middlemen, is drafting

recommendations to present to the Centers for Medicare and

Medicaid Services, Bloomberg reported, citing a reviewed

document.

Proposals under discussion include measures such as

ensuring patients do not pay more than the cash price charged to

uninsured customers, increasing the use of lower-cost

alternatives to expensive biologic drugs and increasing

reimbursement rates for rural and independent pharmacies.